The use of GLP-1 agonists in patients enrolled in a cardiovascular recovery program should be individualized according to the duration and severity of T2DM, having an adjuvant effect in terms of improving endothelial dysfunction, reducing pro-inflammatory status, or improving the lipid profile. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.